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Abstract 
 
Detection of circulating tumor cells (CTCs) has gained increasing attention as scientists and 
physicians learn more about the roles these malignant cells play in metastatic cancer and disease 
progression. Quantification and molecular analysis of CTCs are considered very important because 
they can function as potential indicators of early diagnosis and prognosis of cancer metastasis. 
Therefore, many efforts have been made to develop a reliable method to detect the CTCs. However, 
one major drawback of CTC detection using a conventional microfluidic approach is that it generally 
requires a long and complicated processing time due to its small scale and slow fluid velocity. In 
addition, commonly used immunoaffinity-based positive selection method has a limitation that its 
recovery rate heavily relies on EpCAM expression of target CTCs, which is known to be 
heterogeneous among different cell types. In this thesis, a size-selective lab-on-a-disc platform is 
introduced for a rapid and label-free isolation of CTCs from whole blood. The polycarbonate track-
etch (PCTE) membrane was utilized to isolate CTCs based on the size difference between the target 
cell and other blood cells. Validation of the device was performed using the MCF7 breast cancer cell 
line spiked into PBS buffer solution as well as healthy donor blood. The capture efficiency of 
approximately 50~65 % was achieved with the devised CTC isolation system. The purity of the 
captured cells varied, ranging from 15 % to 30 %. For the clinical studies, patient blood samples from 
gastric cancer and breast cancer patients were tested and analyzed. The number of CTCs ranging from 
5 to 29 CTCs was captured. Overall, the CTC detection rate for the lung cancer patient was 50 %, and 
the detection rate for the gastric cancer patients was 38.4 %.
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CHAPTER 1 Introduction 
 
1.1 Circulating Tumor Cell 
 
1.1.1 Circulating Tumor Cell: Indicator of Cancer Metastasis 
 
Cancer is one of the leading causes of death worldwide, contributing nearly twenty percent of the total 
disease-related mortality.28 In point of fact, however, primary tumor is not the main factor that leads to 
lethal consequences for patients with cancer; instead, it is the metastasis, i.e. the spread of cancer, 
which accounts for the vast majority of cancer-associated deaths.2 For this reason, it is critical for 
clinicians to have reliable diagnostic tools to detect cells that disseminate from primary tumors to 
other parts of the body. Effective isolation and identification of these cells, referred to as circulating 
tumor cells (CTCs), will serve as a better guide for medical diagnosis and treatment as well as an 
excellent prognostic marker for many cancer patients.  
  
As stated above, CTCs are the cancerous cells that reside in the circulatory system, and they are 
known to be the essential components in the process of cancer metastasis. During metastasis, primary 
tumor cells or existing metastatic cancer cells undergo a series of successive steps in order to spread 
the disease to distant organs of a human body (Figure 1). In the initial step of the metastatic cascade, 
tumor cells are detached from the primary tumor site by undergoing a process known as epithelial-
mesenchymal transition (EMT).8, 29 During this process, the cells lose their polarity as well as their 
adhesive capability, permitting them to easily disassociate from their neighboring cells. The cells then 
invade into the surrounding stroma and intravasate into blood vessels nearby the tumor. Once they 
enter the vascular system, the circulating tumor cells, or CTCs, survive in the blood stream until they 
reach a secondary site. Eventually, extravasated CTCs survive and proliferate in a newfound 
microenvironment where pre-metastatic niche is created. CTC dissemination can also occur through 
the lymphatic system. In most cases, however, the cells choose to escape from this route and 
eventually reenter the blood circulation, simply due to the lack of the direct fluid flow from the 
lymphatic system to other organs.8, 30 The investigation of each of the individual step of the metastatic 
cascade is critical for understanding the invasive and migratory properties of CTCs in the patient’s 
body. 
 
Isolation and enumeration of CTCs can certainly play a significant role as a diagnostic tool 
and potential therapeutic target.7, 10 A recent study has discovered that the presence of CTCs in the 
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blood from cancer patients can be associated with both decrease in progression-free survival rate and 
overall survival rate.15 Specifically, for the patients with more than 5 CTCs per 7.5 mL of whole blood, 
the overall survival rate dropped down to approximately 20 % after 17.5 months of the treatment, 
whereas, for the patients with less than 5 CTCs per 7.5 mL of whole blood, the overall survival rate 
was close to 80 % at the same time point (Figure 2b). Additionally, CTC assay was utilized to study 
the effectiveness of clinical therapies. In this study, tumor progression of cancer patients was 
monitored during the course of therapy. It was discovered that, throughout the course of therapy, the 
size of the tumor and the CTC counts have a strong correlation in most cases (Figure 2c).10 From the 
clinical point of view, it is important to be able to sample tumors at particular time points during the 
course of cancer therapy. In this aspect, CTC detection is a suitable tool since the method provides a 
“less invasive alternative” to tissue biopsy which involves highly invasive procedures. Moreover, as it 
can be implied from above clinical studies, CTC assay offers the potential for patient monitoring over 
a period time to help improve selection of individualized therapy. 
 
Figure 1 Diagrammed illustration of cancer metastasis. The sequential steps of metastatic cascade is 
comprised of (a) epithelial-mesenchymal transition (EMT) of tumor cells , (b) degradation of basement 
membrane, (c) intravasation of tumor cells into a blood vessel, (d) dissemination of circulating tumor 
cells in the blood stream, (e) extravasation of tumor cells out of a blood vessel, and (f) proliferation at a 
secondary site.8 
15 
 
 
 
 
Figure 2 Clinical relevance of CTC abundance in patient samples. (a) CTC enumeration results from 
healthy donors, patients with nonmalignant disease, and patients with various types of metastatic 
cancers.7 (b) Comparison of probabilities of overall survival percentage between patients with 
metastatic breast cancer for those with <5 CTCs per 7.5 mL of whole blood and those with CTCs per 
7.5 mL for whole blood.15 (c) The correlation between the change in the number of CTCs (red) and the 
size of the tumor (blue) for four individual patients with (i), (ii) lung, (iii) colon, and (iv) pancreatic 
cancers during the course of therapy.10 
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1.1.2 CTC Detection in Microfluidic System 
 
Throughout the decades, worldwide efforts have been continuously made to develop efficient and 
reliable CTC isolation, enumeration, and characterization methods. As a result, a variety of CTC 
detection methods are now accessible in bench-top research environment. For example, scientists now 
study CTCs by exploiting a variety of technologies including quantitative RT-PCR technique31-32, 
imaging-based approaches33-36, flow cytometry36-38, and microfluidic chip-based techniques10, 39-40. 
Among these techniques, microfluidic chip-based CTC detection has been a fast-emerging research 
area because the device can provide biocompatible environment and its microfabricated structures 
allows precise fluid control. A wide variety of microfluidic chip-based isolation techniques have been 
proposed and some popular separation methods include immunoaffinity-based separation, 
immunomagnetic separation, dielectrophoretic-force based separation, density based separation, and 
size-based separation (Figure 3). In this section, CTC separation technique based first four methods 
will be discussed. Size-based CTC separation method will be discussed separately in chapter 3.  
 
Immunoaffinity-based CTC Isolation 
Immunoaffinity based CTC capture is a method that selectively captures tumor cells from normal 
blood cells by binding with substrate-immobilized antibodies. Toner’s group in Massachusetts 
Institute of Technology (MIT) developed a microfluidic chip which contains freestanding microposts 
functionalized with EpCAM antibodies (Figure 3, Figure 4a).10 Advantage of this system is that a 
whole blood sample can flow directly through the device. The structure is optimized to maintain the 
minimum amount of shear stress; the shear of blood going through the device is calculated to be less 
than blood going through the heart valves during the normal circulations.10 The same group later 
developed a second generation chip named “herringbone-chip,” in order to improve the performance 
 
 
Figure 3 Schematic illustration of current CTC isolation approaches in a blood sample.2  
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of the CTC capture. Newly devised platform further enhances the mixing of the fluids in the channels. 
Specifically, herringbone patterns in the channel ceiling produces vortices within the ﬂow and 
maximize collision between CTCs and the surface of the channel, further increasing the possibility of 
cell-to-surface interactions, thereby a yielding high cell recovery rate.16 Scientists in Toner’s group 
further developed a more advanced version of CTC capture device, referred to as “CTC-iChip.” The 
CTC-iChip consists of three functional modules including hydrodynamics-based cell sorting module, 
inertial focusing module, and magnetophoresis-based enrichment module.12 The advantage of this 
system is that it can be operated in both positive isolation mode and negative depletion mode.  
 
Soper’s group in University of North Carolina, developed a polymer-based microfluidic device 
which contains a series of unique sinusoidal cell capture channels immobilized with anti-EpCAM 
(Figure 4b).20 The device is capable of capturing CTCs directly from whole blood, with high 
efficiency and specificity. Furthermore, in order to perform automatic enumeration of captured target 
cells, the isolated CTCs were released by trypsin and counted using a single-cell conductivity sensor. 
The same group later enhanced the performance of the sinusoidal channel-based CTC isolation system 
by applying additional microfluidic components including the imaging module in addition to isolation 
and enumeration modules.21 
 
Tseng’s group in University of California Los Angeles (UCLA) developed a Velcro-like microchip 
device where they employed electrospun TiO2 nanofibers as a substrate for the anti-EpCAM 
immobilization (Figure 4c). Densely packed TiO2 nanofibers provided more surface area than the flat 
surface for the antibody immobilization, consequently, improving the cell capture performances. This 
group also developed a striking technology that releases captured cells, retaining close to 90 % of the 
viability, by adding temperature-sensitive polymers to the nanofibers.23 
 
Immunomagnetic isolation of CTCs 
Immunomagnetic isolation method is a type of immunoaffinity-based separation where antibody-
antigen interaction is used in conjunction with the external magnetic force. Similarly, EpCAM 
antibodies are tagged with the magnetic nanoparticles, and the magnetic field is applied such that the 
rare CTCs are driven in a magnetic field to be able to allow their isolation. The main factor that 
influences the separation efficiency in this approach is the balance between hydrodynamic force and 
external magnetic force.40 In other words, it is possible to adjust the net force acting on the 
magnetized cells by manipulating the dynamics of the fluid flow in the microchannel, thereby 
collecting the target cells at the specific location inside the channel where the magnetic field strength 
becomes the maximum.40 An example of such type of an approach can be found in the work 
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performed by Zhang’s group in the University of Texas at Austin. They developed a microfluidic 
system that employed a magnetic field gradient as an external force (Figure 4d). The microchip 
consisted of a simple rectangular micro channel in which a stack of neodymium magnets are secured 
underneath25. In this system, the magnetic field gradient was generated between the adjoining magnets, 
efficiently attracting magnetic particle labeled tumor cells at the floor of the channel.  
 
Alternatively, Ingber’s group at Wyss Institute, Harvard focused more on the architecture of their 
magnetic-based separation device. They invented a unique PDMS-based microfluidic chip with the 
magnets placed underneath the collection chambers (Figure 4e). Specifically, the device is comprised 
of a slanted inlet channel that connects to a main collection channel which is then extended in the 
opposite direction to form a “redundant double collection channel.”27 Additionally, multiple rows of 
perpendicularly oriented side chambers are protruded from the main channel and a double collection 
channel. As the fluid passes through the channel, magnetic bead-bound tumor cells are sequentially 
collected in these dead-end side chambers. 
 
Immunoaffinity-based CTC detection methods discussed above heavily depend on the use of the 
EpCAM biomarker to identify the presence of the target CTCs. The EpCAM-dependent CTC 
detection technology is based upon the assumption that the target cancer cells have a sufficient 
EpCAM expression level to readily interact with corresponding antibodies. In reality, however, 
EpCAM expression is highly heterogeneous in different types of tumor cells, and even absent in some 
tumor types which are of nonepithelial origin.41 Moreover, circulating tumor cells are very susceptible 
to degradation, apoptosis, and other real-life phenomena that really cannot be easily recapitulated with 
cancer cell lines.41 Therefore, new enrichment process might be necessary to overcome the pitfall of 
this technology. 
 
Density-based separation 
Density gradient centrifugation is a leukocyte separation technique which can also be applied in CTC 
separation (Figure 3). Using the commercially available Ficoll-Paque PLUS® (Pharmacia-Fine 
Chemicals, Uppsala, Sweden) medium, a solution with a density of 1.077 g/mL, it is possible to 
generate a layered separation of cell types based on cellular density.42 Mononuclear leukocytes and 
circulating tumor cells have similar densities of lower than 1.077 g/mL, whereas densities of other 
cells in blood are higher than 1.077 g/ml.43 As a result of 20 minutes of centrifugation, the bottom 
layer will contain aggregated red blood cells (RBCs), and the layer which is located immediately 
above the erythrocyte layer will mostly consist of granulocytes, having a density high enough to 
migrate through the Ficoll-Paque PLUS layer. Lastly, the leukocytes and CTCs will be located at the 
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interface between the Ficoll-Paque PLUS and plasma layers. The disadvantage of this technique is 
that it provides poor separation efficiency, mainly because of the loss of target tumor cells that might 
be either migrated to the plasma layer or trapped in the aggregates of the RBCs. Furthermore, the 
system is not designed to separation CTCs from leukocytes; therefore, additional steps are necessary 
to increase the purity of the final product. 
 
Electrokinetic Isolation of CTCs 
Electric dipoles can be induced when a non-uniform electric field is applied on the cells; hence, cells 
are considers as a “dielectric bioparticles”.44 Dielectrophoretic (DEP) force-based CTC isolation 
approach takes advantage of the dielectric phenotype of tumor cells. Different types of cells will 
experience different DEP forces because the magnitude and the direction of the force applied on the 
cells partially depend on intrinsic properties of the cells such as membrane capacitance and 
cytoplasmic conductivity.39 Jung’s group in Yonsei University demonstrated the separation of breast 
cancer cells from whole blood exploiting dielectrophoretic separation method together with 
hydrodynamic approach in order to enhance the separation efficiency (Figure 4f).19 DEP-based CTC 
separation method is known as one of the efficient label-free CTC detection methods. However, this 
approach may affect the physiology of the target cells due to the use of a low conductivity medium 
during the separation process.  
20 
 
 
 
 
Figure 4 Examples of CTC separation technologies. (a) CTC capture method using anti-EpCAM 
coated silicon microposts10, herringbone structure16, and inertial focusing method12. (b) CTC separation 
method using anti-EpCAM sinusoidally shaped channels.20-21 (c) CTC separation method using 
immobilized TiO2 nanofibers.23 (d) Immunomagnetic-based CTC separation by employing a magnetic 
field gradient across the microchannels.25 (e) Immunomagnetic-based CTC isolation using dead-end 
side channels for a sequential collection of magnetized tumor cells.27 (f) CTC separation using 
dielectrophoresis (DEP) and multi-orifice force fractionation (MOFF).19 
21 
 
1.1.3 Commercial Technologies for CTC Detection 
 
CellSearch  
The enrichment process of CellSearchTM (Janssen Diagnostics, South Raritan, NJ), the only FDA-
approved CTC detection instrument on the market, involves the use of immunomagnetic-based 
separation technique (Figure 5a,b).1 The system can be used to aid in the monitoring of patients with 
prostate, breast, and colorectal metastatic cancer and predict progression free survival and overall 
survival.1, 15 CellSearchTM utilizes EpCAM antibodies conjugated to ferromagnetic fluid particles as a 
mean of attracting the EpCAM expressed tumor cells. Afterwards, immunostaining procedure is 
performed for the characterization of captured tumor cells using the predefined criteria- DAPI positive, 
CD45 negative, and cytokeratin and 8 and 18 positive. A large number of clinical investigations were 
demonstrated with this system.10, 15, 42 As a semi-automated platform, however, CellSearchTM system 
yield a relatively lower capture efficiency and purity compared to more recently developed 
technologies.42  
 
Isoflux 
IsofluxTM System (Fluxion Bioscience, San Francisco, CA) is another type immunomagnetic-based 
isolation approach which takes advantage of magnetic beads and proprietary microfluidic flow 
focusing technology to achieve high cell enrichment (Figure 5c,d).4 The recovered cells can move 
immediately to downstream molecular analysis including mutation detection, next-generation 
sequencing, and gene expression.4 Limitation of this system is that it requires a long sample 
preparation step, which may adversely affect the enrichment results.   
 
ScreenCell 
ScreenCellTM (ScreenCell, Sarcelles, France) is a simple and robust size-selective CTC enrichment 
device which allows phenotypical, genotypical, and functional downstream characterization of 
captured CTCs (Figure 5e,f).11, 26 Prior to the separation process, the blood sample is treated with a 
proprietary dilution buffer in order to cell fix mononucleated cells and lyse the RBCs. ScreenCellTM 
system can also be applied in separating isolating circulating fetal cells (CFCs), which are known to 
be found in maternal peripheral blood.  
 
Cytotrack 
The basic mechanism of Cytotrack CT4 (Cytotrack ApS, Lyngby, Denmark) scanning system is 
derived from a conventional CD/DVD technology (Figure 5g,h).13 In this system, RBC lysed-blood 
sample including all the leukocytes are immobilized onto a Cytotrack glass disc, which is then coated 
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with a proprietary reagent that binds the cells to the surface of the glass disc. Then, the entire surface 
of the glass disc is scanned within a few minutes. During the scanning, all data are process in real time 
by the control system. The scanner automatically identifies a number of locations on the disc where 
candidates are positioned.  
23 
 
 
 
 
Figure 5 Examples of commercialized CTC detection system. (a,b) CellSearchTM system of Janssen 
Diagnostics LCC, Johnson & Johnson Corp.1 (c,d) IsoFLux SystemTM of Fluxion Biosciences.4 (e,f) 
ScreenCellTM size-selective isolation device from ScreenCellTM.11 (g,h) Cytotrack CT4 scanning 
system from Cytotrack ApS.13  
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1.1.4 Challenges for CTC Studies 
A major challenge that still remains in CTC studies is that the low-abundant target cells must be 
detected in a limited amount of sample. CTCs are extremely rare in whole blood, occurring at a 
frequency as low is 1~10 cells per 106~107 of other blood cells.45 In this regard, the simplest way of 
improving the detection efficiency would be to increase the input volume of the sample. A recent 
study by Lalmahomed et al. used the CellSearchTM system to test the detection rate at different sample 
volume for a group of 15 patients with colorectal cancer.46 They compared the numbers of detected 
CTC in 7.5 mL and 30 mL of whole blood from the same patient. As a result, the median CTC count 
was 1 with a range of 0 to 4 in 7.5 mL of blood, whereas in 30 mL of blood, the median CTC count 
was 2 with a range of 0 to 9. Also, CTCs were found in 13 % of the entire patient samples for 7.5 mL 
assay, and 47 % of the entire patient samples for 30 mL assay. The results indicate that the larger 
sample size might be required for a CTC assay in order to generate a meaningful enumeration 
statistics. However, it is still challenging in microfluidic system to handle a large volume of the 
sample because it requires a long time for a micro-scale chip to process milliliters of blood.  
In addition to low population, the heterogeneity of CTCs is another factor that poses a challenge for 
efficient detection of target cancer cells. For example, even though EpCAM is prominently selected as 
a biomarker for CTCs of epithelial origin, the EpCAM expression level is highly heterogeneous 
among different types of tumor cells. In a nutshell, in order to overcome some intrinsic challenges of 
CTC detection technologies, it is essential to develop a high-throughput CTC detection platform 
which is capable of processing samples with high sensitivity, within a short period of time. 
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1.2 Centrifugal Microfluidics 
 
1.2.1 Theory 
Centrifugal microfluidics, also known as lab-on-a-disc, is a branch of microfluidics that exploits the 
spinning of a disc to induce fluid transfer. As the disc rotates, centrifugal force is exerted on the fluids, 
driving them radially outwards from the center of the disc. For the fluid propulsion, the flow rate 
depends on the rotational speed, radial location of the fluid reservoirs/channels, channel geometry, 
and fluidic properties (e.g. viscosity, density, etc.) of the sample (Figure 6).47 The average velocity, U, 
of the liquid in a microchannel can be derived from centrifugal theory as the following3: 
U =
  
      ̅ 
32  
																																																														Eq. 1 
where hD  is the hydraulic diameter of the channel (defined as PA /4 , where A  is the cross-
sectional area and P  is the wetted perimeter of the channel), r  is the density of the liquid, w  is 
the angular velocity of the disc, r  is the average distance of the liquid in the channels to the center 
of the disc, rD  is the radial extent of the fluid, m  is the viscosity of the fluid, and L  is the length 
of the liquid in the microchannel.3 
 
1.2.2 Diagnostics in Centrifugal Microfluidics System  
The centrifugal microfluidic platform offers many advantages over other microfluidic systems. Only a 
simple rotary motor is necessary to generate forces needed for fluid actuation, while laminar flow-
based microfluidic systems require a complex setup for external apparatus.3 In addition, centrifugal 
microfluidic device have capabilities of valving, mixing, and metering which induces an effective 
fluid control and an efficient mixing of solutions. For these reasons, lab-on-a-disc platforms have been 
utilized in a variety of biomedical applications. One of the examples is the performance of 
immunoassays on a disc. Lee et al. has developed bead-based immunoassay on a lab-on-a-disc for the 
detection of hepatitis B virus (Figure 7b).18 The device offers a full integration, performing steps 
including plasma separation from whole blood, binding of a target sample on the surface of antibody 
conjugated microbeads, washing, reactions with enzymes, and finally, the detection. Furthermore, by 
taking advantage of the fact the disc-based microfluidics is capable of manipulating a complex fluid 
flow by applying active valves in the system, Park et al. devised a fully automated lab-on-a-disc for 
simultaneous detection of multiple protein biomarkers, i.e., fully-integrated multiplex 
immunoassays.48 Sample preparation17, 49, nucleic acid amplification50, DNA microarray 
hybridization22, 51, and cell assays24 are some of other applications that have been performed in a 
centrifugal microfluidic system (Figure 7).  
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Figure 6 Schematic illustration of the centrifugal microfluidics.3 is the average distance of the 
liquid in the channels to the center of the disc,  is the radial extent of the fluid, and  is the 
length of the liquid in the microchannel.3 
 
 
 
Figure 7 Examples of centrifugal microfluidic platforms used in biomedical applications. (a) 
Plasma separation on a disc.17 (b) Fully integrated immunoassay on a disc.18 (c) DNA microarray on 
a disc.22 (d) DEP trapping of yeast cells on a disc.24 
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1.3 Literature Survey: Size-Selective CTC Separation 
 
In this chapter, we will primarily focus on CTC detection platforms which does not take advantage of 
any external forces (e.g. electric filed or magnetic field) or target specific antibodies (e.g. EpCAM 
antibody), but rely exclusively on hydrodynamic characteristics of microfluidic system and the size of 
target cells for separation.  
 
1.3.1 Hydrodynamic Force-driven Separation 
 
The primary assumption underlying hydrodynamic force-driven filtration is that, the fluidic system 
with low Reynolds number where the laminar flow predominates, the particles in the center of the 
defined channel will always follow fluid streamlines. Hydrodynamic cell sorting method separates 
cells based on differences in size of the cells by using specialized microstructures to transport cells to 
desired streamlines through a flow manipulation. Specifically, the flow manipulation can be achieved 
through contracting and expanding the flow by varying the widths of the microchannel. A popular 
hydrodynamic method is “pinched flow fractionation”5. In the work done by Yamada et al., a pinch 
channel was used for guiding the particles of specific sizes to the desired streamline, where they can 
be collected at the end of the extended channel (figure 8a). Once the fluid reaches the end of the 
 
 
Figure 8 Examples of size-based CTC isolation using the hydrodynamic properties of the fluids. (a) 
Particle separation via “pinched flow fractionation” method.5 (b) CTC isolation using the spiral-shaped 
microchannel.14  
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channel, smaller particles can reach streamlines closer to the wall whereas larger particles remain 
traveling along the center of the channel. Another well-known geometry that can be used to separate 
CTCs by hydrodynamic cell sorting method is proposed by Hou et al (Figure 8b).14 Their proposed 
device, a spiral shaped microfluidic channel that consists of double inlets and double outlets, can 
continuously separate tumor and blood cells by the size difference between CTCs and leukocytes. 
Using this system, the obtained the recovery rate of 85 %, and clinical testing was performed as well.  
 
1.3.2 Direct Filtration 
 
It is reported that the size of the CTCs are, on average, larger than ambient blood cells, including 
erythrocytes and leukocytes, in whole blood. Average sizes of CTCs ranges from 12~25 um while 
those of red blood cells and white blood cells are around 1-3 um and 8-12 um, respectively.9 The most 
intuitive approach for separating cells based on size exclusion method is perhaps by mechanically 
filtering target cells using a microsieve structure, which is designed to restrict passages to cells 
smaller than the “critical size.” The microsieve structure can be fabricated through conventional 
microfabrication process including typical photolithography52 or laser ablation53 methods. Advantage 
of using the fabricated membranes, instead of using commercially available track-etch membrane is 
that it is possible to obtain a membrane with a uniform array of well-defined pores.  
 
Lin et al. developed a parylene membrane micro-filter device with circular holes, with a center-to-
center distance between adjacent pores of 20 um (Figure 9a). The capture efficiency using this 
parylene membrane filter was 93 %.9 The size difference between CTCs and human blood cells was 
used to test 57 blood samples from patients with metastatic prostate, breast, colon, or bladder cancer. 
The result demonstrated CTC capture and identification in 51 of 57 patients compared with only 26 
patients in 57 patients using the conventional CellSearchTM method. However, this process resulted in 
low capture cell viability due to the large stresses that developed in the cell membrane during the cell 
capture process.54 Zheng et al. from the same group developed an upgraded version of parylene 
membrane (Figure 9b). The filtration device consisted of two layers of parylene with uniformly 
arrayed pores. The position of the bottom membrane layer was shifted in order to decrease stress 
experienced by the cell during the filtration process. Using this filter, they performed a cell isolation 
experiment and obtain the capture efficiency of approximately 86 %, and this was comparable to their 
previous filtration system. The captured cells were viable and even after 14 days of cell culture 
directly on the device. 
 
Hosokawa et al. introduced a nickel filter with a rectangular micropore array using a conventional 
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photolithography technique (Figure 9c). They compared the recovery rates between the membrane 
circular and rectangular micropores. The recovery rate of captured cells using the membranes with 
rectangular pores was approximately 80 %, whereas the recovery rate using those with circular pore 
only 67 %. In addition, they were able to recover the CTC with higher purity. For the clinical tests, it 
was discovered that the percentage of CTCs in total captured cells was significantly higher on the 
using the membranes with rectangular pores (0.33 %). Table 1 summarizes the recent research in size 
selective filtration-based CTC separation methods. 
  
 
 
Figure 9 Examples of size-based CTC isolation using the direct filtration method. (a) A parylene 
membrane micro-filter device with circular holes. (b) A double-layered parylene membrane. (c) A nickel 
filter with a circular and rectangular micropore array.  
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Table 1 Recent research in size selective filtration-based CTC separation methods. 
*The yield refers to the capture efficiency of target cancer cell lines spiked into whole blood. 
**FC2 buffer is an optimized proprietary dilution buffer used for RBC lysis and cell fixation in the ScreenCellTM system. 
Reference 
Device Performance Sample Treatment Cancer Type Filter Profile 
Yield* 
(%) 
Purity 
(%) 
Flow rate 
(mL/min) 
RBC 
removal 
Dilution 
Pre-
Fixation 
Cell line 
Clinical 
Test 
Material 
Pore size 
(μm) 
Pore density 
(pores/mm2) 
Zheng 
et al.55 
86.5 - 0.1 Lysis 1:10 None LNCaP - Parylene 7 4.4×102  
Lin et al.9 > 90 - 3.8 None 1:1 1 % NBF 
RT3, T4,  
MCF7 
Prostate, 
Colorectal, 
Breast 
Parylene 8 - 
Zheng 
et al.54 
~90 - 2 None 1:10 None LNCaP - Parylene 10 2.9×103 
Desitter 
et al.26 
88.0 - 15 Lysis 3:4 
FC2 
buffer** 
NCI-H2030, 
H1975 
- 
Polycarbonate 
(PC)  
7.5   
6.5  
1×102  
Lim et al.52 > 80 ~5.0 1 None 1:2 None 
HepG2/GFP, 
MCF7, BT474 
Breast, 
Colorectal, 
Prostate 
Silicon 10 5×103  
Coumans  
et al.56 
> 80 ~7.1 1.7 None 1:4 
0.8 % 
PFA 
PC3-9, SKBR3 - 
Polycarbonate 
(PC)  
5  
8 
3.4×103  
9.0×102  
Hosokawa 
et al.57 
~ 80 0.1 200 - - - SCLC, NSCLC Lung Nickel 
9.0 × 30 
(Rectangular) 
3.0×101  
Kim et al.58 68.7 11.8 - 
Density 
gradient 
centrifugation 
None None H358 - Parylene 
8.5 × 8.5 
(Rectangular) 
- 
Hosokawa 
et al.59 
68~100 - 0.2 - - - 
A549, HCC 
827, PC14 
Lung 
Poly(ethylene 
terephthalate) 
(PET) 
8.0 ~ 9.0 - 
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1.3.3 Size Amplification 
 
Kim et al. proposed a CTC isolation platform which takes advantage of the size amplification 
technique along with multi-obstacle filter architecture.6 Unlike other size-based CTC isolation 
methods, antigen-antibody interaction was applied in size amplification. Specifically, the method 
consisted of two sequential processes (Figure 10). First step is the selective size amplification of 
CTCs, which was achieved by conjugating EpCAM coated solid melamine microbeads with cancer 
cells. This permitted avoidance of a size overlap between the CTC and leukocytes. Second step was 
the passing of microbead-conjugated CTCs through a multi-obstacle architecture (MOA) microfluidic 
filter. Their unique platform with multiple obstacles allowed more stable cell capture by reducing the 
shear stress exerted on cells while passing through the device. The recovery rate using this device 
turned out to be 89.7 % (N=7) when 10 cells per 1mL was infused in the system. In addition, white 
blood cells remained in the chip, however, the number ranged from 272~405 cells in each filter chip. 
The major reason for enhanced performance of CTC is distinct size discrimination between the target 
cells and leukocytes.  
 
Figure 10 Schematic illustration of size amplification method using multi-obstacle architecture 
(MOA) filtration device.6 (a) Selective size amplification of CTCs was achieved by conjugating 
EpCAM coated solid melamine microbeads with cancer cells. (b) EpCAM coated solid melamine 
microbeads with cancer cells.  
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1.4 Research Outline 
 
1.4.1 Objectives of the Thesis 
 
One major drawback of CTC detection using a conventional microfluidic approach is that it generally 
requires a long processing time. In the case of isolation methods based on immunoaffinity, for 
example, the system is limited by the number of sufficient interactions between surface-bound 
antibodies and target cancer cells. Although various capture structures such as microposts10 and 
patterned herringbones16 have been shown to increase these interactions, throughputs of such 
platforms still remain within milliliters per hour. In this regard, size-based isolation methods are more 
efficient because these methods have a higher throughput as they are compatible with relatively higher 
ﬂow rates (Table 2). Another advantage of CTC isolation approach based on size differences is that it 
has a potential to capture any type of CTCs regardless of their EpCAM expression level.  
 
The throughput of the CTC isolation system can be further enhanced by exploiting a centrifugal 
microfluidics, or lab-on-a-disc. Compared to the conventional microfluidic system, lab-on-a-disc 
system offers a more efficient fluid control because it does not require external interconnects. 
Furthermore, only a simple rotary motor is necessary to propagate the fluid flow, whereas a complex 
instrumentation is needed in the laminar flow-based microfluidic system.3 In addition, the device can 
be fabricated in inexpensive materials such as polycarbonate, offering the cost-effective 
Table 2 Comparison of different types of CTC isolation system. 
Type of System 
(Approach) 
Throughput Profitability Convenience 
Reference Sample 
Processing Time 
Sample 
Volume 
Material 
Automation & 
Integration 
CTC-iChip 
(Immunoaffinity) 
>3 hours 10 mL Silicon × 
Ozhumer et 
al.12 
CellSearchTM 
System1 
(Immunomagnetism) 
>1 hours 7.5 mL Ferrofluid Δ 
Cristofanili 
et al.15 
MOFF-DEP 
separator 
 (Dielectrophoresis) 
~ 30 min 2 mL PDMS × 
Moon et 
al.19 
Spiral Biochip 
(Hydrodynamic force) 
~1 hour 3 mL PDMS × Hou et al14. 
ScreenCellTM 
System11 
(Direct filtration) 
>3 min 3 mL Polycarbonate × 
Desitter et 
al.26 
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manufacturing process for the mass production. Thus, centrifugal microfluidic system can serve as an 
excellent candidate for the CTC separation platform which requires a rapid and efficient sample 
processing.  
 
The goal of this thesis is to develop a size-selective centrifugal microfluidic system for the rapid 
and efficient isolation and characterization of the circulating tumor cells. The detailed objectives 
for this research project include:  
(i) Fabrication of a biocompatible through-hole membrane for size-selective cancer cell 
separation. 
(ii) Design and fabrication of a membrane-installed high throughput lab-on-a-disc system, 
the CTC-capture disc for capture and detection of cancer cells. 
(iii) Evaluation of the device performance by processing buffer samples and whole blood 
samples at different cell concentration. 
(iv) Performance evaluation of CTC isolation using the cells spiked in whole blood samples 
and patients samples.   
 
 
1.4.2 Outline of the Thesis 
 
The thesis begins with the introduction of the research in Chapter 1. First of all, basic concepts of the 
circulating tumor cell (CTC) and its clinical significance are explained. Next, multiple CTC detection 
methods and commercialized CTC detection systems are briefly discussed, followed by an in-depth 
literature review of the size-based CTC isolation technologies. The concept of a lab-on-a-disc 
platform is also discussed in the end of Chapter 1. In Chapter 2, the process of sample preparation, 
device fabrication, experimental set-ups for cell capture experiments are explained in detail. System 
setup for imaging apparatus is explained as well. In Chapter 3, results and discussion related to the 
device fabrication process and cell separation experiments are discussed in detail. Specifically, size 
distribution of different cancer cell lines and the staining process are discussed first. Next, the 
fabrication of track-etch membrane installed CTC-capture device is explained in detail. Then, the 
performance of the device is evaluated through experimental results of cancer cell-spiked samples and 
patients samples. Chapter 4 proposes future directions of this research, specifically focusing on 
improving the capture efficiency and purity by exploiting the negative depletion method, and using 
the microfabricated through-hole membrane as an alternative for the polycarbonate track-etch 
membrane. Finally, conclusions and future prospects are summarized in Chapter 5.  
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CHAPTER 2 Experimental Methods & Materials 
 
2.1 Sample Preparation 
 
2.1.1 Chemicals and Reagents 
 
For cell culture and passage experiments, following reagents were used: RPMI-1640 and fetal 
bovine serum (FBS) purchased from HycloneTM (Logan, UT, USA); Antibiotic/antimycotic 
solution, 0.25 % Trypsin-EDTA, and 0.4 % Trypan Blue purchased from Gibco® (Grand Island, 
NY, USA); Cell stripperTM purchased from Cellgro® (Manassas, VA, USA); and Dimethyl 
sulfoxide (DMSO) purchased at from Sigma-Aldrich (St. Louis, MO, USA) 
 
For through-hole membrane and CTC-capture disc fabrications, following chemicals and reagents 
were used: SU-8 2025 photoresist and SU-8 developer purchased from MicroChem Corp. 
(Newton, MA, USA); PDMS prepolymer (Sylgard 194) and a curing agent were from Dow 
Corning (Midland, MI, USA); (Tridecafluoro-1,1,2,2-terahydrooctyl)-1-trichlorosilane purchased 
from (UCT Bristol, PA, USA); Methoxypolyethylene glycol amine purchased from Sigma-
Aldrich (St. Louis, MO, USA); and n-(triethoxysilylpropyl)-o-polyethylene oxide urethane (TPU) 
purchased from Gelest (Morrisville, PA, USA) 
 
For cell staining procedure, following reagents were used: Phosphate Buffered Saline (PBS) tablets 
purchased from Ameresco (Framingham, MA, USA); Bovine Serum Albumin (BSA) purchased from 
Bio Basic Canada Inc. (Markham, Canada); Human IgG purchased from (R&D Systems, Minneapolis, 
MN, USA); 4',6-diamidino-2-phenylindole (DAPI) purchased from Sigma-Aldrich (St. Louis, MO, 
USA); Anti-Pan-Cytokeratin- (AE1/AE3) eFluor® 615 and Anti-Human CD45-FITC purchased from 
eBioscience (San Diego, CA, USA); Anti-Cytokerain- PE* purchased from BD Bioscience (San Jose, 
CA, USA); 35 % Formaldehyde solution purchased from Samchun Chemical (Kyunggi, Korea); and 
Triton X-100 purchased from Biossesang Inc. (Kyunggi, Korea).  
 
2.1.2 Blood Specimen Collection and Processing  
 
All blood samples, including healthy donor blood samples and patient blood samples were collected 
after an Institutional Review Board (IRB) approval. For patient blood samples, blood was drawn from 
10 lung cancer patients and 13 gastric cancer patients from Pusan National University Hospital. All 
Blood samples were stored in EDTA tubes (BD Vacutainer, Becton, Dickinson and Company, USA) at 
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4oC to avoid blood coagulation. Samples were processed within 12 hours after collection to ensure 
white blood cells are still viable.  
 
2.1.3 Cancer Cell Lines 
 
Cell culture and passage 
MCF7 breast cancer cell lines, AGS gastric cancer cell line, and PC3 prostate cancer cell lines were 
used in this research. All the cell lines were purchased from American Type Culture Collection 
(Manassas, VA, USA) were cultured in RPMI Medium with 5% FBS and 1% antibiotics/antimycotics. 
Cell lines were grown in humid environment at 37oC and 5 % CO2. The cells were sub-cultured at 
regular intervals. They were exposed to 1 mL of Cell stripperTM for 3 minutes and suspended in 
1xPBS buffer to harvest the cells. Centrifugation conditions for live cells and fixed cells were 2500 
rpm (600 g) for 3 min and 13200 rpm (16100 g) for 1 min, respectively. The condition was 
determined to keep from possible cell rupture or cell losses. Only passage cells from passages 2 to 20 
were spike into 1xPBS buffer or whole blood samples for spike-in experiments. 
 
Cell staining 
MCF7 cells were stained using a predefined criteria for CTC characterization: DAPI for nucleus 
staining, Cytokeratin for a CTC identification and CD45 for leukocyte identification. Specifically, 
concentrations of staining solution used per test was as following: 100 ng/mL of DAPI, 8 μg/mL of 
Anti-Pan-Cytokeratin- eFluor® 615, 240 ng/mL of Anti-Cytokerain- PE*, and 4 μg/mL of Human 
CD45- FITC. For the staining process, the cells were first blocked with 500 μg/mL of Fc blocker 
(Human IgG) for 15 minutes to at RT, followed by washing step with 0.5 % BSA in 1xPBS buffer 
solution. Then, the cells were fixed with 4 % paraformaldehyde for 15 minutes at RT, followed by a 5 
minutes of permeabilization with 0.1 % Triton X-100 in 0.25 % BSA in 1xPBS solution. Then, the 
cells were incubated with a staining cocktail of DAPI, CK and CD45 for 20 minutes at RT. Lastly, 
washing step with 0.5 % BSA was performed in order to remove any excess of stain solutions.  
 
Rare cell counting 
CTC studies deal with a rare number of cells, as few as 1~10 cells per given volume of sample. 
Therefore, for spike-in experiments, it is critical to be able to obtain low numbers of cells with high 
accuracy. Schematic illustration of a rare cell counting process is shown in Figure 11. For the counting 
of 1~10 cells, 1μL with approximately 20 cells were loaded on a cell culture dish. After most of the 
cells sediment, the pipette tip was carefully positioned at the loaded cell solution. Individual cells 
were carefully suctioned while looking under the microscope. For the counting of 50 ~ 200 cells, 1μL 
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with approximately 50~200 cells were loaded on a cell culture dish and counted under a microscope. 
Then, 9 μL of 0.25 % Trypsin-EDTA solution was loading directly on the loaded cell. After 30 
seconds of incubation, the entire solution (10 μL) was repeatedly pipetted several times to ensure all 
the cells inside the solution are detached. Then, 10 μL of cell solution was suctioned carefully. After 
the retrieval of the cells, the surface of the dish was scanned under a microscope to locate any possible 
non-specifically adsorbed cells. For the counting of 1000~10000 cells, cell solutions of desired 
numbers of cells were acquired via serial dilution process. Using a hemocytometer, equal volumes of 
the cells from the same stock solution was counted three times, to confirm the cell concentrations. 
Pipette tips were always blocked with 0.5 % BSA in 1xPBS buffer solution prior to suctioning of cells 
to avoid cell adherence to the surface of the tips. 
 
 
 
 
 
 
 
Figure 11 Schematic illustration of a rare cell counting process. (a) Cell counting protocols for 1~10 
cells. (b) Cell counting protocols for 1~10 cells. (c) Cell counting protocols for 1000~10000 cells.  
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2.2 Device Fabrication 
In this section, fabrication methods for the polycarbonate CTC-capture disc, disc operation process, 
and imaging process are briefly explained. Detailed disc fabrication results and evaluations will be 
elaborated in chapter 3.  
 
2.2.1 Fabrication of the CTC-capture Disc 
 
Disc Fabrication 
The CTC-capture disc was designed with Solidworks 3D CAD design software (Waltham, MA, USA). 
Designed feature was fabricated using a CNC milling machine (M&I CNC Lab, Osan, Korea). 
Polycarbonate plates and sheets (PC: I-Components Co. Ltd, Korea) were used to create four 
individual device layers (1 top layer, 2 middle layers, and 1 bottom layer) of the CTC-capture disc 
(Figure 20). The thickness of the PC plates for each layers were 0.5 mm, 1 mm, 5 mm, and 1 mm, 
from top to bottom. Adhesive layers were separately designed and were incised using a cutting plotter 
(CE3000-60; Graphtec Corp., Japan). Fabricated PC device layers and adhesive layers were then 
appropriately bonded together using a pressure sensitive adhesive layer (DFM 200 clear 150 POLY H-
9V-95, FLEXcon, USA). More detailed descriptions of the fabrication process the CTC-capture 
device are discussed in Chapter 3. 
 
Polycarbonate Track-etch (PCTE) Membrane Installation 
Commercially available hydrophilic polycarbonate track-etched membrane (PCTE) membranes 
(WhatmanTM, Florham Park, NJ, USA) were utilized in spike-in experiments. Track-etched 
membranes with the diameter of 13 mm, and the pore sizes of 5 μm and 8 μm were used in this 
research. Membrane was chemically bonded to the PC substrate by applying acetone to a bonding 
area.  
 
2.2.2 Surface Passivation 
 
The surface passivation was investigated by using three different types of reagents and chemicals: 1 % 
BSA, 1% Poly(ethylene glycol)bis(amine) (PEG-amine), and 1 % thermoplastic polyurethane (TPU). 
All the surfaces were cleaned with isopropyl alcohol (IPA) and sonicated in deionized water for 5 
minutes prior to the experiments. The PEGylation of the PC surfaces, including the CTC-capture 
device and the track-etched membrane, the substrates were first treated with the oxygen plasma under 
the condition of 70%, 50 sccm, for 1 minutes (Cute plasma system; Femto Science, Korea), Then, the 
plasma treated substrates were incubated in 1% PEG-amine and diisopropylethyl amine for 2 hours at 
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RT, followed by a washing step with ethanol a final drying step. For the reaction with TPU, PC 
surfaces were treated under the same oxygen plasma condition (70 %, 50 sccm, 1 min). The substrates 
were treated with 1 % v/v TPU solution in ethanol for 2 hours at RT. After the incubation step, the 
substrates were washed with ethanol, baked at 80°C, and subsequently sonicated in ethanol for 3 min 
and dried. For analysis, contact angles for each surface were measured (goniometer; ramé-hart 
instrument co., Succasunna, NJ, USA).  
 
2.3 System Settings  
 
2.3.1 Disc-based Microfluidic System 
 
The visualization system was used for the disc-based CTC capture experiments (Visualization System; 
HanRa Precision Eng Co., Korea). The disc operation system used in this experiment is composed of 
four individual modules: imaging module, motion control module, laser control module, and finally, a 
PC (Figure 13a). The imaging device is used to monitor and record the fluidic movements of the 
rotating disc, and is comprised of four individual components, which are CCD camera, lens, strobe 
light and manual stage. The camera installed in the imaging device is a CCD digital camera (IK-TF5C, 
Toshiba America, Inc., USA) in which video signal can save the 60 frame per 1 sec. For the motion 
control module, the device consists of a rotor, laser stage, magnet stage and controller. The rotor 
(SGMJV-02A 200W servomotor, Yaskawa Electric Co., Japan) offers a maximum rotational speed of 
6000 rpm. Control PC contains software which is able to execute operations based on the pre-
designed operating program. Using this software, it is possible to design the operating program of disc 
by manipulating variables including rotating speed, mixing frequency, laser irradiation, and position 
along with as saving conditions of image files. Laser irradiation and mixing tools were not utilized in 
this project. The operation program for the disc-based CTC isolation was created as shown Table 3.  
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Table 3 The operation program for the disc-based CTC isolation. 
No. 
Staining 
Process 
Fluidic State Volume  
Flow 
condition 
Time 
1 
Sample 
Filtration 
Flow 1 mL  2400 rpm* 15 sec 
30 sec 
2 Washing Flow 1 mL 1200 rpm 15 sec 
4 Fc Blocking Incubation 300 μL - 15 min 
50.8 min  
5 Washing Flow 500 μL 1200 rpm 15 sec 
6 Fixation Incubation 300 μL - 15 min 
7 Permeabilization Incubation 300 μL - 5 min 
8 Washing  Flow 500 μL 1200 rpm 15 sec 
9 Staining Incubation 300 μL - 15 min 
10 Washing Flow 500 μL 1200 rpm 15 sec 
 Total Processing Time 51.3 min 
* 2400 rpm is the maximum spin speed used for blood samples. Lower spin speed was applied for less viscous 
blood samples.  
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2.3.2 ScreenCellTM System 
 
Figure 13b shows the experimental setup for ScreenCellTM filtration system. For the sample 
preparation process, four parts of ScreenCellTM FC2 buffer solution was added to three parts of blood 
samples, and the mixed sample was homogenized by inverting the tubes at least 5 times. ScreenCellTM 
FC2 buffer is a buffer solution made from ScreenCellTM which is known to fix and lyse the cells 
simultaneously. The volume of the blood samples used was the experiment was fixed to 1 mL. The 
diluted blood sample was then incubated for 8 minutes at RT. After the sample preparation step, the 
blood sample was loaded on module (i) of the ScreenCellTM Cyto Filtration Unit (Figure 14c). Then, 
VacutainerTM tube was inserted to module (ii) in order to induce the sample filtration by vacuum. 
When the liquid reached the bottom of module (i), 1xPBS buffer solution was added to module (i) for 
a washing step. At the end of the filtration process, the filtration unit was disassembled to release the 
membrane. For staining procedure, the sequence of events and the concentrations of the reagents as 
well as the incubation times were identical as described in previous sections.  
 
2.4 Imaging 
 
Scanning Electron Microscopy (SNE 4500M; SEC E-Beam Pioneer, Korea) was used for the 
inspections of fabricated PDMS through-hole membrane. The samples were coated with gold prior to 
the inspection (SEC E-Beam Pioneer, Korea). For the characterization of captured cells, fluorescent 
inverted microscope (IX71; Olympus Corp., Japan) was utilized. The images of captured cells were 
analysed by using image analysis software (Metamorph, Molecular Devices, USA).  
 
 
 
Figure 12 The system settings for (a) disc-based microfluidic system and (c) ScreenCellTM filtration 
system.  
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2.5 Fabrication of the PDMS Through-hole Membrane 
 
Commercially available polycarbonate track-etch membranes consist of randomly distributed 
cylindrical pores. Random distribution of pores may result in the fusion of pores, and this would 
negatively affect cell isolation results by providing target cells with more chances of escape through 
the fused pores. For an alternative approach, it is possible to fabricate the membranes which have 
uniformly arrayed through-holes. The polydimethylsiloxane (PDMS)-based through-hole membrane 
fabrication method introduced in this section is the reproduction of the fabrication technique described 
in Choi et al.53 Results of PDMS membrane fabrications are discussed in more in depth detail in 
chapter 4.  
 
Patterns of the through-hole membrane were designed using a AutoCAD® software (Autodesk, San 
Rafael, CA, USA) which were then translated onto commercially fabricated chrome mask 
(MicroImage; Choongchung, South Korea). SU-8 Master for the membrane was fabricated by 
utilizing a standard photolithography technique. The fabrication process started with the spincoating 
of SU-8 negative photoresist on a bare silicon substrate (Etech, South Korea). SU-8 2025 photoresist 
was spincoated at 1800 rpm for 30 seconds on a 6” <100> P- type silicon wafer to obtain 
approximately 45 μm thickness of photoresist. Spincoated wafer was then soft baked at 65oC for 4 
minutes and at 95oC for 6 minutes, sequentially, followed by UV exposure through the photomask 
(SUSS MicroTec, Garching, Germany). The photomask and the PR-coated silicon wafer were 
extensively cleaned with nitrogen gas prior to exposure step. Patterned wafer was then baked at 65oC 
for 4 minutes and at 95oC for 4 minutes. Finally, the patterned wafer was developed by submerging 
the wafer in SU-8 developer for 15 minutes.   
 
Prior to a PDMS casting process, the surface of the fabricated SU-8 master was silanized with 
(Tridecafluoro-1,1,2,2-terahydrooctyl)-1-trichlorosilane. SU-8 master and the silanizing agent was 
placed inside the vacuum desiccator for 4 hours, forming the silane monolayer on the surface of the 
master. The casting of PDMS was performed by a conventional soft lithography process. A 1:10 
mixture of a curing agent and PDMS prepolymer was poured onto a SU-8 master. Poured PDMS was 
then degassed in a vacuum desiccator for 6 hours in order to remove possible air bubbles trapped 
inside the pre-cured PDMS. Subsequently, degassed PDMS was baked in 65oC overnight and 
carefully demolded from the SU-8 master.  
 
The next step was the surface passivation of the PDMS replica and the slide glass using a RIE 
apparatus (TTL, Korea). The surface of the PDMS mold was treated with CF3 plasma under 50 sccm, 
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300 W treatment conditions for 100 seconds, and the surface of the slide glass was treated with the 
same gas plasma under 50 sccm, 15 W treatment conditions. Afterwards, the protruded patterns of the 
PDMS mold were faced with the slide glass in conformal contact. A pair of permanent magnets was 
then placed on both sides to the hold molding black. Then, the empty space between the PDMS mold 
and the slide glass was gently filled with a 1:5 mixture of a curing agent and PDMS prepolymer. The 
molding block was put in a vacuum desiccator to remove air bubbles trapped in the PDMS gel, and 
was backed at 80oC for 4 hours. Lastly, the cured PDMS membrane was gently detached from the 
PDMS mold and the glass slide. 
 
The final step of the membrane fabrication was the removal of the PDMS residual layer using the 
same RIE apparatus (TTL, Korea) used in the surface passivation of the PDMS mold and the slide 
glass. The surface of the PDMS membrane slightly etched with SF6 (90 sccm)/ O2 (6sccm) gas 
combination under the RF power of 500 W for 100 seconds. The etch rate was 0.47 ± 0.02 um/ min. 
RIE apparatus. The schematic illustration of the PDMS through-hole fabrication process is 
summarized in Figure 12.  
 
Figure 13 Schematic illustration of PDMS through-hole membrane fabrication process. The 
fabrication process consists of 6 individual steps: (a) SU-8 negative PR spincoating; (b) Soft bake, 
UV-exposure, and development; (c) Pouring of PDMS gel onto a SU-8 master; (d) Surface 
passivation; (e) Filling of PDMS gel; (f) Detachment of the PDMS membrane; (g) removal of the 
PDMS residual layer. 
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CHAPTER 3 CTC Isolation on a Centrifugal Microfluidic Device 
 
3.1 Performance Metrics 
 
The key objective of the CTC isolation technology is to efficiently capture rare cancer cells from 
blood sample, where the contaminant cells constitute the majority of the total cell population. In this 
research, two performance metrics- capture efficiency and purity- were applied to evaluate the 
performance of the devised CTC isolation platform. First of all, it is important to be able to isolate 
CTCs with high and consistent capture efficiency because the accurate enumeration of CTCs in 
patient blood samples is critical especially in clinical studies. As described in equation 1, the capture 
efficiency, which is also known as the recovery rate or capture yield, is the defined as the percentage 
of the number of captured target cancer cells in the initial number of input target cells: 
Capture	Efficiency =
      	     	     
      	     	       
× 100																																Eq. 2				 
In this study, the number of input target cells is defined as the verified number of target cells infused 
in the syringe or the loading chamber of the capture device. The number of the input cell was proven 
to be accurate by optimizing the rare cell counting protocol proposed in chapter 2.  
 
Secondly, the purity of captured cells is another important factor for the rare cell separation 
technology. As summarized in equation 2, purity is the percentage of the number of target cancer cells 
in total number of captured cells including any hematologic cells: 
Purity = 	 
      	     
     	     
 
     
× 100																																									Eq. 3			 
Purity of the output samples may vary among different blood samples even when the performance of 
the device is consistent because the numbers of leukocytes vary significantly among individuals. In 
the CTC studies, purity usually refers to the fraction of the captured cancer cells relative to the sum of 
the target cancer cells and white blood cells, or leukocytes. This is due to the fact the majority of the 
red blood cells are eliminated prior to processing the sample by lysing the RBCs or selectively 
excluding them via density gradient-based separation method. However, RBC elimination step is 
sometimes not required if the CTC isolation device is capable of efficiently sorting out RBC 
contaminants without any clogging issues.  
 
Overall, capture of CTCs at high efficiency and high purity is considered critical in CTC isolation 
technology in order to proceed with downstream molecular analyses including mutational or genomic 
analyses with captured target cells.  
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3.2 Preliminary Studies 
 
3.2.1 Size Distribution of Different Cancer Cell Lines 
 
The sizes of the cancer cells can vary even within a particular cell line. Prior to performing the cancer 
cell isolation experiments using the devised CTC capture devices, the sizes of the cancer cell lines 
were measured in order to determine the average sizes as well as the size variation of different types 
of cell lines, including MCF7 breast cancer cell line, AGS gastric cancer cell line, and PC3 prostate 
cancer cell line. Figure 14a summarizes the average sizes and variations of three different types of 
cancer cell line and leukocytes. The average sizes of MCF7, PC3, and AGS cell lines ranged from 12 
μm to 15 μm (N=20), whereas, the average size of the WBC was smaller than 8 μm. Figure 14b shows 
the bright field image and immunofluorescence images of MCF7 cells filtered on the PCTE 
membrane. The size of the MCF7 cells were directly compared with the 8 μm pores of the PCTE 
membrane to determine the size difference between the cells and the pores. 
 
 
 
 
 
 
Figure 14 The cell size analysis of cancer cell lines. (a) The average sizes and variations of three 
different types of cancer cell line, MCF7, AGS, and PC3, and leukocytes. The dashed line 
represents the pore size of the PCTE membrane. The scale bare represents 20 μm. (b) Fluorescence 
image of isolated MCF7 breast cancer cells on a PCTE membrane. The size of the MCF7 cells 
compared to 8 μm pore of the PCTE membrane. The scale bare represents 10 μm. 
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3.2.2 Optimization of the Staining Protocol 
 
Target cancer cells can be stained with fluorescent antibodies prior to the enumeration step to identify 
and distinguish them from other contaminant blood cells. In this study, breast cancer cell-line MCF7 
was stained using a predefined criteria for CTC characterization: DAPI for nucleus staining, 
Cytokeratin for a CTC, and CD45 for leukocyte identification. The optimal staining condition was 
determined by varying the concentration of each staining solution and altering the order of the steps of 
the staining procedure. Optimized concentrations of each staining solutions was as following: 100 
ng/mL of DAPI, 8 μg/mL of Anti-Pan-Cytokeratin- eFluor® 615, 240 ng/mL of Anti-Cytokerain- PE, 
and 4 μg/mL of Human CD45- FITC. Two different staining methods were performed to determine 
the more favorable order of sequence for the staining procedure. In method 1, the cells were first 
blocked with Fc blocker in order to block non-specific staining, followed by a washing step with 0.5 % 
BSA in 1xPBS buffer solution. The cells were fixed with 4 % paraformaldehyde followed by the 
permeabilization step with 0.1 % Triton X-100. Finally, the cells were incubated with a staining 
cocktail of DAPI and CK. and CD45. In method 2, the sequence of the event was identical except for 
the CD45 incubation step, where CD45 was stained prior to fixation and permeabilization steps. The 
purpose of switching the order of CD 45 incubation step in method 2 to was to further prevent non-
specific staining of target cancer cells with CD45. Figure 15 summarizes the result of the staining 
process using both method 1 and method 2. It can be concluded that cancer cells and leukocytes are 
clearly distinguished using the first method. However, it was difficult to identify leukocyte using 
method 2, when the CD45 incubation step was performed before the fixation step.  
 
 
Figure 15 Fluorescence images of fluorescently labeled MCF7 breast cancer cells. The sequence of 
staining method 1 is Fc blocking – fixation – permeabilization – DAPI, CK, and CD45 staining. The 
sequence of staining method 2 is Fc blocking – CD45 staining – fixation – permeabilization – DAPI 
and CK staining. The scale bare represents 10 μm. 
46 
 
3.3 Optimization of Device Fabrications 
 
3.3.1 Disc Design 
 
For the CTC-capture disc, the device consisted of the loading chamber, inlet channel, filtration zone, 
outlet channel, and the waste chamber (Figure 16). The size of the device was 60 mm in diameter, and 
the thickness of the device was approximately 7.5 mm. The volume capacity of the loading chamber 
and waste chamber were approximately 1200 μL and 2100 μL. The inlet channel, which had a depth 
of 1 mm, started from the loading chamber and it was directly connected to the filtration zone. The 
width of the inlet channel was as wide 10 mm, and this minimized the fluidic resistance which could 
adversely affect the cells, which are contained within the fluid sample. Filtration zone consists of the 
upper space, polycarbonate track-etch membrane, and lower upper space. As the disc rotates, fluids 
contained in the loading chamber would be transferred to the filtration zone, initially filling up the 
upper space of the filtration zone. Then the fluid would be filtered via inserted track-etch membrane. 
Similar to CTC-capture disc, the layers consisted of 0.25 mm top PC layer, 0.1 mm pressure sensitive 
adhesive layer, 1 mm middle PC layer, 0.1 mm pressure sensitive adhesive layer, mm body PC layer, 
and 0.1 mm pressure sensitive adhesive layer. Polycarbonate track-etch membrane was inserted in the 
groove from the back side of 5 mm body PC layer. 
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Figure 16 Illustration of the centrifugal microfluidic device for CTC isolation. PC track-etched 
membrane is bonded underneath the body layer. (a) Front-view of the disc design (b) The layer 
composition is as follows: (i) 0.25 mm top PC layer, (ii) 0.1 mm pressure sensitive adhesive layer, (iii) 1 
mm middle PC layer, (iv) 0.1 mm pressure sensitive adhesive layer, (v) 5 mm body PC layer, and (vi) 
0.1 mm pressure sensitive adhesive layer. (c) Side-view of the disc design showing the fluid flow pattern 
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3.3.2 Membrane Installation 
 
As mentioned in the previous section, carbonate track-etch membrane, which has the thickness of 10 
μm, was inserted in the groove from the back side of the 5 mm body PC layer (Figure 17a). The 
membrane was chemically bonded using acetone by partially dissolving the bonding area of the 
membrane. Specifically, a drop of acetone was loaded onto the edges of the bonding area, and it 
spread through the edges of the membrane by the capillary action. In order to determine the integrity 
of the membrane-bonded disc under hydrodynamic flow conditions, an aqueous solution of red dye 
was infused in the loading chamber of the membrane installed disc (Figure 17b). As a result, it was 
confirmed that the membrane bonding was successful and leakage was not observed even when the 
device was operated at 4200 rpm with the maximum loading volume, 1200 μL. In the case of the 
CTC-capture chip, the leakages did not occur with a flow rate as high as 1 mL/min. In addition, the 
delamination of the device rarely occurred even at maximum loading volume and the spinning 
condition. The reproducibility of the chemical bonding method was 97.3 % (N=110).  
  
 
 
Figure 17 Result of the leakages test on a CTC-capture disc. (A) Cross-section images of the 
filtration zone. (B) Operation images of the CTC-disc. The chamber was filled with 1 mL of 
aqueous dye solution and the device was operated at 4200 rpm.  
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3.3.3 Surface Passivation 
 
Surface passivation of the polycarbonate (PC) substrate was a mandatory step in order to prevent a 
non-specific adsorption of the biomolecules including target cancer cells. In order to select the surface 
treatment condition with maximum surface passivation efficiency, six different surfaces were used, 
including controls, pristine PC substrate. Five different surface treatment methods included 1 % BSA 
treatment on both pristine PC surface and plasma treated PC surface, TPU modified PC surface, and 
lastly, PEG treated PC surface. The result of the surface treatment was confirmed with measuring the 
contact angles of each surface. It was determined that pristine PC had the average contact angle of 
85.3 degrees while other modified surfaces had smaller contact angles ranging from 7.62 degrees 
(plasma treated PC surface) to 58.5 degrees (PEG treated surface). Table 4 summarizes the contact 
angle analysis of substrates with six different surfaces.  
 
 
 
Table 4 Summary of the contact angle analysis of six different surfaces using various surface 
passivation methods.  
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Performance of surface passivation was confirmed by loading the MCF-7 cancer cell lines on each 
surface modified substrate. Initially, approximately 100 cells were loaded on each surface. After 5 
minutes of incubation, loaded 1xPBS buffer solution with cells was retrieved followed by an intensive 
washing step. Afterwards, remaining numbers of cells on the surface of the substrates were counted. 
As a result, over 70 % of the cells remained on the surface in the case of pristine and plasma treated 
PC substrates. The substrate that had the lowest number of remaining cells was 1 % BSA treated 
substrate, which had approximately 15 % of the cells remained on the surface. Considering that cells 
are not incubated for over 5 minutes during cell capture experiments, it was concluded that it was 
efficient enough to treat 1 % BSA on a pristine PC surface in order to effectively prevent the non-
specific cell adsorption on the surface of the CTC capture device. Figure 18 summarizes the 
effectiveness of the different types of passivation methods.  
 
 
 
Figure 18 The result showing the effectiveness of the different types of passivation methods. 
Over 70 % of the cells remained on the surface in the case of pristine and plasma treated PC 
substrates. The substrate that had the lowest number of remaining cells was 1% BSA treated 
substrate, which had approximately 15 % of the cells remained on the surface. 
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3.4 Cell-line Experiments 
 
3.4.1 Determination of the Spin Condition 
 
When dealing with the fluid that contains fragile cells, it is important that the pressure difference 
across the porous membrane is kept below a threshold value where cells will be damaged. When the 
fluid flows through an orifice, or a pore, in a laminar condition, the relationship between the flow rate 
(Q) and the pressure drop (ΔP) across the orifice can be summarized as following60:   
Q =
  Δ 
3 
 1 +
8 
3  
 
  
																																																								Eq. 4		 
where r is the radius of the orifice, μ is the coefficient of dynamic viscosity, which is 3-4 cP in case of 
blood61, and L is the depth of the orifice, or the channel height of the “flow channel.” The relationship 
between the flow rate and the pressure drop can be modified as in equation 4, when multiple circular 
pores are present in the membrane with the thickness L62-63:  
Δ =   Q =  
128  
   
+
24 
  
 
 
 
 ( )																																									Eq. 5 
where R is the membrane resistance per unit area, N is the number of pores , k is the fraction of open 
area of the pores, d is the pore diameter, L is the pore depth (i.e. thickness of the membrane). The 
function f(k) in equation 4 is defined as the following64: 
 ( ) = 1 −    
(   )
  
 
   
																																																			Eq. 6 
Above equation is an infinite series solution with the first three coefficients (i.e. a1, a2, a3) equal to 
0.334, 0.111, and 0.066, respectively. The relationship between the pressure drop across the porous 
membrane and the flow rate can be further simplified if the viscous losses in the porous membrane are 
neglected, and the open area, k, of the membrane is less than 10 % since the function f(k) converges to 
unity. Thus, the final equation simplifies to65: 
Δ =  
24 
  
 ∙
 
 
																																																														Eq. 7 
In this section, the pressure difference across the membrane in the CTC-capture disc system was 
calculated by my measuring the flow rate of the blood sample at different spinning conditions, 1200 
rpm, 2400 rpm, and 3600 rpm. Determined pressure drop for each condition was compared with the 
pressure drop across the membrane in the ScreenCellTM system. Figure 19 summarizes the result of 
variation of pressure drop across the membrane at different filtration settings. The line (a) represents 
the theoretical relationship between the pressure drop and the flow rate in the ScreenCellTM system, 
where the red square indicates the resulting pressure drop at the flow rate of 15.31 mL/min, which is 
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the flow rate generated during the filtration process. The line (b) represents the theoretical relationship 
between the pressure drop and the flow rate in the CTC-capture disc system. Blue square indicates the 
resulting pressure drop at the flow rate of 19.05 mL/min, 40.54 mL/min, and 72.29 mL/min. It was 
concluded that the pressure drop across the porous membrane in ScreenCellTM was 872.1 Pa, which 
falls in the range of the pressure drops generated in 1200 rpm, 2400 rpm, and 3600 rpm condition in 
the CTC-capture disc system, which were 480.0 Pa, 1036.2 Pa, and 1839.6 Pa, respectively. 
 
 
 
 
 
 
Figure 19 Variation of pressure drop across the membrane at different filtration settings. (a) 
Theoretical relationship between the pressure drop and the flow rate in the ScreenCellTM system. The 
red data point represents the resulting pressure drop at the flow rate of 2.55x10-7 m3/s. (b) Theoretical 
relationship between the pressure drop and the flow rate in the CTC-capture disc system. Black data 
points represent the resulting pressure drop at the flow rate of 19.05 mL/min, 40.54 mL/min, and 
72.29 mL/min. 
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3.4.2 Capture Efficiencies at Various Flow Conditions 
 
The cell capture experiment was performed in order to confirm the validity of the operation conditions 
of the CTC-capture disc system. The samples were processed using CTC-capture disc at the spinning 
condition of 1200 rpm, 2400 rpm, and 3600 rpm. For each trial, approximately 100 MCF7 breast 
cancer cells were spiked into healthy donor blood sample. For the comparison of capture efficiencies 
with the ScreenCellTM systems, approximately 100 MCF7 breast cancer cells were spiked into the 
identical donor blood.  
 
Figure 20 summarizes the result of the capture efficiencies at various conditions. As it can be seen in 
the case of the disc system, the capture efficiencies ranged from 43.3 %~ 55.2 % regardless of 
different spinning conditions. It was concluded that, within the range of 1200 rpm to 3600 rpm, the 
differences in the angular velocity of the spinning disc do not significantly affect the cell capture 
efficiency.  
 
The cell capture experiment was repeated using the fixed spin condition of 2400 rpm in order to 
compare the performance of the device with the ScreenCellTM systems. For the sample preparation 
process, 1.3 mL of ScreenCellTM FC2 buffer solution was added to 1 mL of MCF7 cell spiked blood 
samples for both samples. Mixed samples were homogenized by inverting the tubes multiple times 
followed by the 8 minutes of incubated step. Diluted blood samples were processed afterwards. As 
summarized in Figure 21, in the case of the CTC-capture disc system, the capture efficiency was 
approximately 61.4 %, whereas the capture efficiency using the ScreenCellTM systems was 
approximately 71.6 %. Although the capture efficiency of cells using the CTC-capture disc is slightly 
lower than that in ScreenCellTM systems, it can be concluded that the separation performance of the 
CTC-capture disc is comparable to the ScreenCellTM systems considering the fact that sample 
handling in the ScreenCellTM systems is more straightforward compared to the handling in the CTC-
capture disc system.  
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Figure 20 The effect of the angular velocity of a rotating disc on the cancer cell capture efficiency 
and purity. 
 
 
 
Figure 21 Comparison between different filter devices. (a) Capture efficiencies of cancer cells 
using ScreenCellTM System and CTC-capture disc (2400 rpm). Bright-field images above the bar 
graphs are the representative images of the PCTE membrane inserted in each device. (b) 
Fluorescence images of the cells captured from ScreenCellTM System (top) and CTC-capture disc 
(bottom). The scale bar represents 10 μm. 
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3.4.3 Capture Efficiencies at Different Cell Concentrations 
 
In CTC studies, the efficient isolation of the cancer cells is critical especially when the cell 
concentration of the input sample is considerably low. In this section, the capture efficiency was 
evaluated at various input cell concentrations ranging from 1 cell to 150 cells in 1 mL of sample in 
order to evaluate the consistency of the capture efficiency at different cell concentrations. The 
experiment was performed with the MCF7-spiked 1xPBS buffer solution as well as MCF7-spiked 
whole blood sample. The spin rate of the disc was 2400 rpm.   
 
Figure 22a shows the recovery of MCF7 cells spiked into 1 mL of 1xPBS buffer solution and healthy 
whole blood sample at cell concentrations ranging from 1 cell to 1000 cells. The overall capture 
efficiency of the MCF7 cells in 1xPBS buffer solution was slightly above approximately 50.5 %, 
which was similar to the capture efficiencies obtained when the cell line was spiked into whole blood 
samples (53.3 %). In addition, the r2 value which was close to unity indicated that capture efficiency 
result at each cell concentration was fairly consistent.  
 
Figure 22b shows the capture efficiency and the purity of MCF7 cells spiked into whole blood 
samples at cell concentrations ranging from 1 cell to 150 cells. In this experiment, the purity of the 
captured cells was evaluated along with the capture efficiency of the input cancer cell. The result of 
the capture efficiency using the whole blood sample was 53.3 %, which was similar to the capture 
efficiency obtained when the cells were spiked into 1xPBS buffer solution. Isolated number of 
leukocytes varied, ranging from 200 cells to 800 cells. Theoretically, the number of the leukocytes 
should remain consistent because the experiment was performed with the blood samples from the 
identical donor. Variations in the number of leukocyte may have resulted from the damages of cells 
during the disc operation. Another possibility can be that the staining of the CD45 was not efficiency 
performed.   
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Figure 22 (a) The capture efficiency of MCF7 cells spiked into 1X PBS buffer solution (black) and 
whole blood sample (red) at cell concentrations ranging from 1 cell to 150 cells. (b) The capture 
efficiency (red) and the purity (black) of MCF7 cells spiked into whole blood samples at cell 
concentrations ranging from 1 cell to 150 cells.  
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3.4.4 Dilution Factor 
 
In most of the proposed CTC isolation platforms, the dilution of whole blood samples is sometimes 
necessary in order to avoid the leakage or the clogging of the red blood cells. Processing the undiluted 
whole blood sample, which is indeed an unfavorable condition, may result in a lower capture yield of 
the target cells. In this section, the effect of the dilution factor on the capture efficiency was studied. 
As shown in Figure 23, three different blood sample conditions were used. For the diluted blood 
samples, 1 mL of whole blood was diluted with 250 μL and 500 μL of 1xPBS buffer solutions, 
respectively. As a result, it was concluded that the dilution factor is not the critical component which 
affects the capture efficiency of the target cancer cells. Furthermore, the purity of the captured cells 
did not vary significantly at different ratio of dilution factors. 
 
 
 
 
 
Figure 23 The effect of the dilution factors on the cancer cell capture efficiency and purity. 
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3.5 CTC Isolation from Patient Blood 
 
3.5.1 Clinical Tests 
 
For the clinical evaluation, 10 lung cancer patients and 13 gastric cancer patients in Pusan National 
Hospital were enrolled in the study. Patient blood samples were processed within 6 hours, and 
different volumes of whole blood samples ranging from 2.2 mL to 4.4 mL were directly loaded onto 
the device for the CTC isolation experiment. Experiment for the sample L64 was not successful 
because the RBCs from the sample caused the clogging of the membrane during the filtration process. 
All other samples were process without any technical difficulties. Figure 24 is the summarized result 
showing the performance of CTC-capture disc using clinical samples. The number of isolated CTCs 
from lung cancer patients ranged from 5 CTCs to 21 CTCs, and those from gastric cancer ranged from 
5 CTCs to 29 CTCs. All counts were normalized to 7.5 mL, the input volume used in CellSearchTM 
System9, in order to directly compare the number of captured CTC in a fixed volume of blood sample.  
 
Table 5 is the list of lung cancer patient samples and gastric cancer patient samples with the individual 
CTC counts. The CTC detection rate for the lung cancer patient was 50 %, and the detection rate for 
the gastric cancer patients was approximately 38.4 %. Considering the fact that the capture 
efficiencies from the spike-in experiments were approximately 60 % in most cases, the 50 % of the 
CTC detection rate in the patient sample experiments offers the indication of a considerably high 
detection rate. In order to increase the detection rate, it is essential to increase the input sample 
volume to generate a statistically meaningful enumeration data.  As it can be inferred from Table 6, 
the detection rate of the CTC-capture disc is comparable to the FDA-cleared CellSearchTM system. 
The CTC detection rate of other microfluidic system ranged from 60 % to 100 %. However, it not 
valid to draw any firm conclusions from the enumeration results of patient samples. In other words, 
the effectiveness of each platform cannot be determined by simply comparing the CTC counts due to 
heterogeneity of patient samples.  
 
Figure 25 shows representative immunofluorescence images of CTCs and WBCs obtained from lung 
cancer patients and gastric cancer patients. It can be inferred from the images that the size of the 
CTCs varies in a wide range. The size distribution of the isolated CTCs from gastric cancer patients 
was compared with that of AGS gastric cancer cell line by measuring the diameter of each cell via 
Metamorph image analysis software (Figure 26). The size of the cells ranged from 6 μm to 22 μm, 
and the average size of the CTCs from gastric cancer patients was larger than the average size of the 
AGS gastric cancer cell line.  
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Figure 24 Results showing the performance of CTC-capture disc in clinical samples. Various volumes 
of blood samples were used in the experiment, and the result was normalized to directly compare the 
number of captured CTC in 7.5 mL of blood sample, which is the fixed input volume used in Cellsearch 
System.9 (a) The CTC isolation result of 10 lung cancer patients (b) The CTC isolation result of 13 
gastric cancer patients.  
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Table 5 List of lung cancer patient samples and gastric cancer patient samples showing the number of 
captured CTCs with the stage information.  
* Immunofluorescence detection was not possible due to an RBC clogging of the membrane.  
** Stage information was unidentified. 
  
 
 
 
Sample 
No. 
Cancer 
Type 
Stage 
Number 
Number of 
Captured CTCs 
Sample 
Volume (mL) 
CTCs/ 7.5 mL of Blood 
L58 Lung IIA 5 3.2 11.7 
L59** Lung - 0 2.4 0 
L60 Lung IIIB 0 3.6 0 
L61 Lung IV 0 4 0 
L62 Lung IV 4 2.4 12.5 
L63 Lung IIIA 16 4.4 27.3 
 L64* Lung IB - 4.4 - 
L65 Lung IB 5 2.2 17.0 
L66 Lung IV 21 3.6 43.8 
L68 Lung IV 0 3 0 
G110 Gastric IIIB 0 3.2 0 
G111 Gastric IIIC 0 4.2 0 
G113 Gastric IIIC 0 4.2 0 
G115 Gastric IA 15 3.2 35.2 
G118 Gastric IIIC 18 4.4 30.7 
G119 Gastric IV 29 3.6 60.4 
G120 Gastric IIIC 9 3.6 18.8 
G121 Gastric IIA 0 3.6 0 
G122 Gastric IIIB 5 3.6 10.4 
G123 Gastric IA 0 3.6 0 
G124 Gastric IIIB 0 4 0 
G125** Gastric - 0 3.4 0 
G126 Gastric IA 0 4.2 0 
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Figure 25 Gallery of CTCs and leukocytes captured using the size-selective CTC-capture disc from lung 
cancer patients (L62 and L63) and gastric cancer patients (G115 and G118). Cells were stained with 
DAPI (nucleus), PE-labeled anti-cytokeratin (CTC), and FITC-labeled anti-CD45 (leukocyte). The scale 
bare represents 10 μm. 
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Figure 26 Histogram plots showing the size distribution of the CTCs isolated from (a) gastric 
patient blood samples (orange), and cancer cells from AGS gastric cancer cell line (slashed light 
orange), and (b) lung patient blood samples (purple). The size of the cancer cells ranges from 6 
μm to 22 μm. 
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Table 6 Summary of the clinical evaluation results using different types of CTC isolation systems. 
* Detection rate refers to the fraction of the number CTC detected cancer patients compared to the total number of tested cancer patients. 
CTC Isolation System 
(Approach) 
Capture 
Efficiency(%) 
Cancer Type 
Total 
Number of 
Patients 
Detection Rate* 
(%) 
No. of CTCs 
Processed 
Sample Volume 
(mL) 
Processing 
Time 
Reference 
CellSearchTM System 
(Immunomagnetism) 
42 
Colorectal 
Breast 
12 
11 
33.3 
54.5 
1-22 
1-114 
(per processed volume) 
7.5 > 3 hours Lin et al.9 
Micropost Chip 
(Immunoaffinity) 
65 Prostate 36 63.8 16-292 
(per processed volume) 
0.9- 5.1 > 3 hours 
Nagrath et 
al.10 
Herringbone Chip 
(Immunoaffinity) 
> 90 Prostate 15 93.0 12~3,167 
(per mL) 
- ~30 min Stott et al.16 
CTC-iChip 
(Immunoaffinity) 
> 90 Prostate 41 90.2 0.5-610 
(per mL) 
6- 12 ~3 hours 
Ozkumur el 
al.12 
Micro-Velcro Chip 
(Immunoaffinity) 
80-95 Prostate 40 - 1-99 
(per mL) 
- 2 hours Lu et al.66 
Slanted Spiral Chip 
(Hydrodynamics) 
~80 
Lung 
Breast 
5 
5 
100 
100 
3-125 
(per mL) 
7.5 4.4 min 
Warkiani et 
al.67 
ScreenCellTM System 
(Direct filtration) 
~80 
Cutaneous 
Melanoma 
23 70 0-11 
(per processed volume) 
2 > 3 min 
Schuur et 
al.11  
Filter-based Chip 
(Direct filtration) 
> 90 
Colorectal 
Breast 
12 
11 
83.3 
100 
2-26 
1-60 
(per processed volume) 
7.5 - Lin et al.9 
Filter-based  
CTC-capture Disc 
50-65 
Lung 
gastric 
10 
13 
50 
38.4 
5-21 
5-29 
(per processed volume) 
2.2-4.4 > 3 min Lee et al. 
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3.6 Conclusion 
 
Size-based isolation methods are more efficient because these methods have a higher throughput as 
they are compatible with relatively higher ﬂow rates. In this chapter, a label-free lab-on-a-disc 
platform was introduced for a rapid and efficient detection of CTCs from whole blood samples as well 
as clinical samples. Polycarbonate track-etch membrane was used to isolate CTCs based on the size 
difference between the target cell and other blood cells. The device was tested with MCF-7 cancer cell 
spiked in both 1xPBS buffer solution as well as whole blood sample. The capture efficiency of the 
target cancer cell using the devised system ranged from 50 % to 60 %, and the purity of the captured 
cells varied widely, ranging from 15 % to 30 %. In addition, blood samples from gastric cancer and 
breast cancer patients were tested. The number of CTCs ranging from 5 to 29 CTCs was captured. 
Overall, the CTC detection rate for the lung cancer patient was 50 %, and the detection rate for the 
gastric cancer patients was 38.4 %. 
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CHAPTER 4 Future Directions 
 
4.1 Negative Depletion 
 
The capture efficiency and the purity of cancer cells using the proposed CTC-capture disc ranges from 
50~65 % and 15~30 %, respectively. In this chapter, two ideas are proposed in order to further 
enhance the performance of the device. First of all, negative depletion strategy can be applied for a 
sample pre-treatment step prior to the size selective cell separation step. Negative enrichment method 
is a cell enrichment technique where non-target cells are captured and removed, instead of selectively 
capturing target cancer cells. The negative enrichment technique many not be efficient if it is used as a 
main detection method. However, it can be beneficial if it is applied prior to the main detection step, 
since it is possible to remove wanted background cells, such as leukocytes, beforehand, consequently 
leading to an enhanced purity of the final product.  
 
4.2 PDMS Through-hole Membrane Fabrication 
 
Another way to enhance the sensitivity of the device is to use a microfabricated through-hole 
membrane. As discussed previously, random distribution of pores in PCTE membrane may result in 
the fusion of pores, which would result in lower cell capture efficiency results by allowing target cells 
to escape through the fused pores more easily. In this section, a biocompatible membrane which 
uniformly arrayed through-holes was fabricated by taking advantage of micromachining technologies. 
The polydimethylsiloxane (PDMS)-based through-hole membrane fabrication method introduced in 
this section is the reproduction of the fabrication technique described in Choi et al.53  
 
4.1.1 Mask Design 
 
The desired dimension of the PDMS through-hole membrane is 13 mm in diameter with an effective 
filter area of 10 mm, with the thickness of 45~50 μm, and the pore size of 8 μm was selected for the 
final product. In addition the patterns with pore size larger than 8 μm were designed for the purpose of 
confirming the validity of the fabrication process. Throughout the experiment, pore sizes of 8 μm, 10 
μm, 12 μm, and 20 μm were used. In term of the spacing between each pores, center-to-center 
distance between adjacent pores was 36 μm for the designs with pore sizes of 8 μm, 10 μm, and 12 
μm, For the design with a pore size of 20 μm, the center-to-center distance between adjacent pores 
was 30 μm. The open areas or the membrane design with pore sizes of 8 μm, 10 μm, 12 μm, and 20 
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μm were 4.5 %, 7.0 %, 10.0 %, and 22.7 %, respectively. Circular patterns around the membrane were 
added to the final design in order to avoid the collapsing of the membrane during the PDMS-gel 
filling step (Figure 12e). As mentioned in Chapter 2, the patterns were designed by using a 
AutoCAD® software. Figure 27 is the example of one of the mask design that was used for the 
membrane fabrication experiments.  
 
4.1.2 SU-8 Master Fabrication 
 
The fabrication of SU-8 mold is the initial step of the PDMS through-hole membrane fabrication 
(Figure 12a). SU-8 master for the membrane was fabricated by utilizing a standard photolithography 
technique. The process starts with the spincoating of the SU-8 negative photoresist on a bare silicon 
substrate. The desired thickness of the final product is approximately 45~50 μm. Using the optimized 
spincoating condition (1800 rpm for 30 seconds), it was possible to obtain the uniform thickness of 
approximately 45 um. Spincoated wafer was then soft baked at 65oC for 4 minutes and at 95oC for 4 
minutes, sequentially. 
 
It is important to have clear-cut and accurate profile characteristics of microstructures especially when 
the fabricated product is used as a master for a subsequent PDMS mold generation. Specifically, it is 
imperative that the sidewalls of the micro-trenches are vertical in order to obtain the PDMS replica 
 
 
Figure 27 Example of the mask design used for through-hole membrane fabrication. Three of the four 
types of membrane features were designed in this mask. The center-to-center distance between 
adjacent pores was 36 μm. 
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with intact straight pillars. Patterns with a positive draft angle (i.e. γ> 90) will have the diameter of the 
micro-trench wider at the top (Wt) than it is at the bottom (Wb) (Figure 28). In this case, frictional 
resistance between the SU-8 mold and replicated PDMS microstructure will increase during the 
demolding step, and this may cause a defect in both the SU-8 mold and PDMS replica. In other words, 
it is likely that PDMS replica will be torn apart, leaving the remnant PDMS remain trapped inside the 
trench. If the walls of the trenches are perfectly vertical with draft angle of zero degree (γ= 90 in 
Figure 28a), demolding process will become relatively easier since the removal process of the PDMS 
replica from the SU-8 mold will only involve the initial detachment and possibly the frictional sliding 
along the interface between molded PDMS and the SU-8 cavity wall.68 Consequently, it is critical to 
reduce undercuts by precisely controlling the draft angles of the micro-trenches in order to use such a 
high aspect ratio (HAR)-arrayed structure for a subsequent PDMS mold generation. 
 
As mentioned previously, the target pore size and membrane thickness is 8 μm and 45~ 50 μm, 
respectively, resulting with the aspect ratio ranging from 5.6:1~ 6.6:1. Fabricating such a high aspect 
ratio of SU-8 patterns requires an appropriate UV exposure dosage, which is a critical factor that 
determines the verticality as well as the dimensional accuracy of the microstructure. The optimal UV 
condition for the patterning of SU-8 photoresist was 180 mJ/cm. Furthermore, minimal and uniform 
proximity gap between the mask and wafer was maintained throughout the UV exposure step in order 
to minimize the diffraction error.69  
 
Development was the final step of the SU-8 mold fabrication procedure. Development of narrow and 
deep trenches of patterned SU-8 mold required a submergence of the wafer in the SU-8 developer for 
at least 15 minutes. As a result, it was possible to obtain a SU-8 mold with micro-arrayed trench 
patterns with the size as small as 8 μm. Figure 29 is the results of the fabricated SU-8 master. 
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Figure 28 (a) Schematic illustration of the microstructures with undercuts. Wt, Wb, γ, and h represents: 
top widths, bottom widths, and height, respectively. (b) Representative cross-sectional SEM image 
showing the microstructures with undercuts (700x). The diameter of the micro-trench at the top is 11.9 
μm while it is 12.9 μm at bottom.  
 
 
Figure 29  Results of SU-8 master fabrication. (a) A photograph image of a fabricated 8U-8 master.  
(b-d) Representative cross-sectional SEM images showing images showing the cross-sections of the SU-
8 molds with trench diameters of (b) 8 μm, (c) 12 μm, and (d) 20 μm in diameter. Magnifications are 
400x, 500x, and 400x, respectively.  
69 
 
4.1.3 PDMS Master Fabrication 
 
PDMS is one of the most commonly used silicon-based organic polymer in a variety of microfluidics 
and bioMEMS applications because it is cheap, transparent, biocompatible, and easy to handle.70 
Among various different candidates including silicon or thermoplastics, PDMS was selected as the 
mold for the through-hole membrane, particularly because it is a highly flexible material with the 
shear modulus (G) of approximately 250 kPa at a room temperature.  
 
Prior to a PDMS casting process, the surface of the fabricated SU-8 master was passivated with 
(tridecafluoro-1,1,2,2-terahydrooctyl)-1-trichlorosilane in order to minimize the force of friction that 
will be exerted by each surface (i.e. the sidewall of the trenches in SU-8 mold and the surface of the 
PDMS pillar) on the other. The casting of PDMS was performed by a conventional soft lithography 
process. As a result, it was possible to acquire vertical and straight PDMS pillars for those that had 
diameters of 20 μm and 12 μm. However, the PDMS pillar with the diameter of 10 μm and 8 μm 
resulted with significant deformations in most cases (Figure 30b).   
  
PDMS mold can deform during the demolding process, and deformed PDMS structures have a 
tendency to return to its original shape owing to its high elasticity. However, in the case of protruding 
structures with high aspect ratio, it is likely that, in some cases, the structures will experience a 
bucking or a collapse.71 One reason that can explain this phenomenon is that the protruding structures 
experience high frictional force when they are being detached from the mold, even after the surface of 
the PDMS mold is carefully passivated. Specifically, the stress caused by the frictional force can 
exceed the maximum mechanical strength of the microposts if the diameter of the microposts is too 
small. This will eventually cause the protruding microstructures to either break off or collapse.72  
 
The stability of the PDMS microposts can be dependent upon their own weight.72 According to Roca-
Cusachs et al., for the micropost that has a height of h a diameter of b, the critical aspect ratio (the 
maximum aspect ratio of the micropost free from the risk of collapsing) is dependent on b-1/3.71 This 
indicates that as the diameter of the post decreases, it become more difficult to attain higher aspect 
ratio microstructure. In a nutshell, stability of the demolded PDMS microstructure is dependent upon 
two factors: frictional force exerted during the detachment and the weight of the microposts. These 
factors may have caused the microstructures structures with pillar diameter less than 10 μm to 
collapse, as shown in Figure 30b.  
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Figure 30 Results of PDMS master fabrication. (a) A photograph of a demolded PDMS masters. (b) 
Representative side-view SEM image showing the failure-mode of PDMS mold with a pillar diameter 
of 8 μm. Representative cross-sectional SEM images of PDMS masters with pillar diameters of (c) 12 
μm, and (d) 20 μm in diameter. For Figures (b), (c), and (d), magnifications are 400x, 200x, and 400x, 
respectively. 
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4.1.4 Surface Passivation and Demolding of PDMS Membrane 
 
The critical step prior to using the demolded PDMS microposts as a second master for the PDMS 
through-hole membrane fabrication was the surface treatment of the PDMS molds and the slide glass 
which would be facing the pillar-side of the PDMS mold in conformal contact (Figure 12d). Since the 
PDMS mold had an extremely high surface area with densely packed micropost array, it was likely 
that the resulting membrane will remain attached to the PDMS mold after a detachment. Peeling off 
the membrane from a thickly packed micropost array may cause a breakage of the micropost 
structures. Thus, the surface condition was manipulated so that the demolded PDMS through-hole 
membrane will remain on the slide glass.  
 
Instead of (tridecafluoro-1,1,2,2-terahydrooctyl)-1-trichlorosilane which was used for SU-8 mold 
passivation, the surface was treated with CF3 plasma for the fine controls of the treatment conditions. 
The treatment condition was optimized using two different variables, with the fixed gas pressure of 50 
sccm: RF power and the duration of the plasma treatment. The effect of the surface treatment was 
analyzed by measuring the contact angles of each substrate. Table 6 summarizes the result for the 
PDMS surface passivation, and Table 7 summarizes the surface passivation result for the slide glass 
with nine different conditions. In the case of the surface treatment of the PDMS mold, contact angles 
ranged from 87.71± 2.64o to 92.73± 3.29o; the results were not significantly different from one another. 
In the case of the surface treatment of the slide glass, however, the contact angles varied from 12.9 ± 
1.21o to 100.7± 2.21o. For the final condition, RF power of 300W for 100 seconds was selected for the 
surface treatment of the PDMS molds. For the condition for the slide glass, RF power of 15 W for 10 
seconds was selected.  
 
In order to fill the PDMS gel in a space between the membrane and the slide glass, passivated PDMS 
mold was first faced with the slide glass in conformal contact. Then, a pair of permanent magnets was 
then placed on both sides to the hold the molding block. Then, the empty space between the PDMS 
mold and the slide glass was gently filled with a 1:5 mixture of a curing agent and PDMS prepolymer. 
A 1:5 mixture of the curing agent and PDMS was used because it was less viscous compared to a 1:10 
mixture, allowing a more effective filling of the PDMS gel. The molding block was then baked at 
80oC for 4 hours. Lastly, the cured PDMS membrane was gently detached from the PDMS mold and 
the glass slide. The optimized surface treatment condition mentioned above allowed a smooth 
detachment of the membrane from the PDMS mold, keeping it slightly attached on the slide glass 
surface. Figure 31 is the result showing the detached PDMS membrane from the PDMS mold.  
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Table 7 The surface passivation results for the PDMS mold with different conditions. 
 
 
Table 8 The surface passivation results for the slide glass with different conditions. 
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4.1.5 Back-side Etching 
 
Above membrane casting process often resulted in a thin residual PDMS layer left behind on the 
membrane because it is difficult to obtain PDMS microposts with perfectly vertical edges. The final 
step of the membrane fabrication was, therefore, the removal of the PDMS residual layer. The surface 
of the PDMS membrane was slightly etched with SF6 (90 sccm)/ O2 (6sccm) gas combination under 
the RF power of 500 W for 100 seconds. The etch rate was determined to be 0.47 ± 0.02 μm/ min. As 
a result, it was possible to remove residual PDMS layers. Figure 32 summarizes the final result of the 
PDMS through-hole membrane with uniformly arrayed through-holes. 
 
 
 
Figure 30 Results of PDMS through-hole membrane fabrication. Representative SEM images 
showing images showing front side (a) and back side (b) of the PDMS through-hole membrane with 
the hole size of 12 μm. Representative SEM images showing images showing front side (c) and back 
side (d) of the PDMS through-hole membrane with the hole size of 20 μm. Magnifications are 600x, 
700x, 500x, and 400x respectively. 
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Figure 31 Results of PDMS through-hole membrane fabrication after the completion of back-side 
etching. (a) A photograph of the final product. Representative SEM images showing images 
showing front side (b, d) and back side (c, e) of the same PDMS through-hole membrane with hole 
sizes of 12 μm. Magnifications for Figures (b), (c), (d), and (e) are 80x, 70x, 600x, and 500x, 
respectively.   
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4.1.6 Performance Evaluation 
 
For the proposed membrane fabrication method, two critical aspects remained unsolved. First of all, 
the membrane fabrication using proposed fabrication method was not as efficiency reproducible as 
expected. Multiple steps of the fabrication process, including SU-8 mold fabrication, PDMS casting, 
surface passivation of the PDMS mold and a slide glass, PDMS gel filling, and the detachment, 
resulted with a long turn-around time. Furthermore, fabrication of the membranes using a high aspect 
ratio feature was a very challenging process. Specifically, it was difficult to obtain the PDMS mold 
with the micropost diameter of 8 μm. The possible reason for this may be due to the fact that the 
diameter of the micropost compared to its height was too small to withstand the frictional force 
exerted on the thin and flexible microposts, leading to serious structural deformations of the 
microposts. In order to overcome difficulties mentioned above, it is possible to take advantage of 
alternating membrane fabrication methods including laser ablation method73 or dry-etching methods74.  
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CHAPTER 5 Concluding Remarks 
 
5.1 Summary of the Work 
 
In this chapter, a label-free lab-on-a-disc platform was introduced for a rapid and efficient detection of 
CTCs from whole blood samples as well as clinical samples. Polycarbonate track-etch membrane was 
used to isolate CTCs based on the size difference between the target cell and other blood cells. The 
device was tested with MCF-7 cancer cell spiked in both PBS buffer solution as well as whole blood 
sample. The capture efficiency of the target cancer cell using the devised system ranged from 50 % to 
60 %, and the purity of the captured cells varied widely, ranging from 15 % to 30 %. In addition, 
blood samples from gastric cancer and breast cancer patients were tested. The number of CTCs 
ranging from 5 to 29 CTCs was captured. Overall, the CTC detection rate for the lung cancer patient 
was 50 %, and the detection rate for the gastric cancer patients was 38.4 %. The negative depletion 
method prior to the filtration is proposed in order to increase the purity of the product for a 
downstream molecular analysis. In addition, PDMS through-hole membrane with regular size and 
alignment was fabricated to use it as an alternative for the filer, and it is expected to enhance the 
sensitivity of the device.  
 
5.2 Strength and Limitation 
 
The strength of the proposed CTC-capture disc is that it requires less than 3 minutes to process whole 
blood samples. Considering that most of the immunoaffinity-based CTC isolation platforms require at 
least a few hours to complete the sample processing procedure, our system, which exploits size-based 
filtration method on a lab-on-a-disc system, significantly reduces the process time. Another advantage 
of our work is that the CTC isolation processes do not require sample pre-treatment step. In other 
words, the whole blood sample can be directly loaded onto the disc. Owing to these advantages, the 
CTC-capture disc platform can be highly competitive candidate for a point-of-care testing (POCT) 
device in the field of cancer diagnosis. However, the system still has a room for improvement. Since 
our CTC-capture disc platform is not yet an automated system, it requires a trained expert to run the 
samples in order to avoid experimental errors pertaining to technical discrepancies.   
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5.3 Future Prospect 
 
For the future work, the automation of the system is essential to minimize the turnaround time of the 
entire process, starting from the sample infusion step to the detection step. This is possible by 
applying automated unit operations, i.e. active valving, mixing, and metering, onto the lab-on-a-disc 
platform. By taking advantage of the unit operations, it is also possible to integrate additional 
detection modules directly onto our CTC-capture disc. This will provide us with a more rapid and 
efficient way of performing downstream molecular analysis, including quantitative PCR and Next 
Generation Sequencing.  
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